Providence Therapeutics Enrolls First Patient in World's First Clinical Trial of a Personalized mRNA Vaccine for Pediatric Brain Cancer
CALGARY, AB, & MELBOURNE, Australia, Nov. 18, 2026 /PRNewswire/ -- Providence Therapeutics, Inc., a clinical-stage biotechnology company specializing in messenger RNA (mRNA) vaccines, today announced that enrolment has started for the PaedNEO-VAX clinical trial, a world-first study evaluating personalized mRNA cancer vaccines for children and...




